A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection

Olivera-Ugarte, Santa-Mariela; Bolduc, Marilène; Laliberté-Gagné, Marie-Ève; Blanchette, Léa-Jeanne; Garneau, Caroline; Fillion, Maude; Savard, Pierre; Dubuc, Isabelle; Flamand, Louis; Farnós, Omar; Xu, Xingge; Kamen, Amine; Gilbert, Megan; Rabezanahary, Henintsoa; Scarrone, Martina; Couture, Christian; Baz, Mariana; Leclerc, Denis

doi:10.1016/j.nano.2022.102584

Cited by 8 publications

(4 citation statements)

References 74 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it should be noted that non-stabilized S glycoprotein vaccines have been shown to provide protection as well, albeit at lower efficacy. This is in line with the abovementioned immune dominance of the RBD, which is most likely sufficiently exposed in non-native conformations of S. Indeed, numerous vaccine candidates composed of only RBDs demonstrated the significant immunogenicity and generation of neutralizing antibodies [ 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 ]. Furthermore, since the RBD contains conserved epitopes that are recognized across most circulating clades, specifically targeting conserved epitopes within the RBD may generate SARS-CoV-2 vaccines with broader cross-variant neutralization and thus protective activity [ 141 , 142 ].…”

Section: Importance Of Glycoprotein Stabilization For Vaccine Develop...supporting

confidence: 71%

SARS-CoV-2 S Glycoprotein Stabilization Strategies

Pedenko

Sulbarán

Guilligay

et al. 2023

Viruses

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has again shown that structural biology plays an important role in understanding biological mechanisms and exploiting structural data for therapeutic interventions. Notably, previous work on SARS-related glycoproteins has paved the way for the rapid structural determination of the SARS-CoV-2 S glycoprotein, which is the main target for neutralizing antibodies. Therefore, all vaccine approaches aimed to employ S as an immunogen to induce neutralizing antibodies. Like all enveloped virus glycoproteins, SARS-CoV-2 S native prefusion trimers are in a metastable conformation, which primes the glycoprotein for the entry process via membrane fusion. S-mediated entry is associated with major conformational changes in S, which can expose many off-target epitopes that deviate vaccination approaches from the major aim of inducing neutralizing antibodies, which mainly target the native prefusion trimer conformation. Here, we review the viral glycoprotein stabilization methods developed prior to SARS-CoV-2, and applied to SARS-CoV-2 S, in order to stabilize S in the prefusion conformation. The importance of structure-based approaches is highlighted by the benefits of employing stabilized S trimers versus non-stabilized S in vaccines with respect to their protective efficacy.

show abstract

Section: Importance Of Glycoprotein Stabilization For Vaccine Develop...supporting

confidence: 71%

SARS-CoV-2 S Glycoprotein Stabilization Strategies

Pedenko

Sulbarán

Guilligay

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic caused a devastating impact on many sectors of human life, caused millions of people to lose their lives and became an exceptional public health crisis that urgently demands the development of timely and accurate therapeutics. Over the past years, during the COVID-19 pandemic, tremendous research efforts and financial resources have been dedicated to the development of diagnostic, prophylactic, and therapeutic measures for COVID-19 [ 29 , 73 , 74 ].…”

Section: Neutralizing Monoclonal Antibodies Against Sars-cov-2mentioning

confidence: 99%

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Widyasari

Kim

2023

Antibodies

View full text Add to dashboard Cite

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of SARS-CoV-2 variants raised concerns about these therapies’ efficacy and long-term viability. Studies reported several antibodies, that received authorization for COVID-19 treatment, are not effective against new variants or subvariants of SARS-CoV-2, hence their distribution has to be paused. Here, the authors reviewed the status of the currently available monoclonal antibodies for COVID-19 treatment, their potential as a therapeutic agent, and the challenges ahead. To address these issues, the authors presented general information on SARS-CoV-2 and how monoclonal antibodies work against SARS-CoV-2. The authors then focus on the antibodies that have been deployed for COVID-19 treatment and their current status, as well as the evidence supporting their potential as an early intervention against COVID-19. Lastly, the authors discussed some leading obstacles that hinder the development and administration of monoclonal antibodies for the treatment of COVID-19.

show abstract

“…In recent studies, slightly different PapMV VLPs based on PapMV CP and synthetic RNA have been used successfully. This type of PapMV VLP is assembled in vitro and con-sists of PapMV CP expressed in E. coli and the non-coding ssRNA in vitro transcript [43][44][45][46]. Mathieu et al (2013) [43] demonstrated that the administration of PapMV VLPs to mice using the intranasal route triggered a strong innate immune response.…”

Section: Helical Plant Virusesmentioning

confidence: 99%

Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy

et al. 2023

View full text Add to dashboard Cite

Vaccines are the cornerstone of infectious disease control and prevention. The outbreak of SARS-CoV-2 has confirmed the urgent need for a new approach to the design of novel vaccines. Plant viruses and their derivatives are being used increasingly for the development of new medical and biotechnological applications, and this is reflected in a number of preclinical and clinical studies. Plant viruses have a unique combination of features (biosafety, low reactogenicity, inexpensiveness and ease of production, etc.), which determine their potential. This review presents the latest data on the use of plant viruses with different types of symmetry as vaccine components and adjuvants in cancer immunotherapy. The discussion concludes that the most promising approaches might be those that use structurally modified plant viruses (spherical particles) obtained from the Tobacco mosaic virus. These particles combine high adsorption properties (as a carrier) with strong immunogenicity, as has been confirmed using various antigens in animal models. According to current research, it is evident that plant viruses have great potential for application in the development of vaccines and in cancer immunotherapy.

show abstract

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection

Cited by 8 publications

References 74 publications

SARS-CoV-2 S Glycoprotein Stabilization Strategies

SARS-CoV-2 S Glycoprotein Stabilization Strategies

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy

Contact Info

Product

Resources

About